Logo do repositório
 
Publicação

Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic review

dc.contributor.authorSavelkoel, Jelmer
dc.contributor.authorBinnendijk, Klaas Hendrik
dc.contributor.authorSpijker, Rene
dc.contributor.authorvan Vugt, Michèle
dc.contributor.authorTan, Kathrine
dc.contributor.authorHanscheid, Thomas
dc.contributor.authorSchlagenhauf, Patricia
dc.contributor.authorGrobusch, Martin Peter
dc.date.accessioned2023-09-26T14:10:18Z
dc.date.available2023-09-26T14:10:18Z
dc.date.issued2018
dc.description© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/)pt_PT
dc.description.abstractBackground: We evaluated existing data on the prophylactic efficacy of atovaquone-proguanil (AP) in order to determine whether prophylaxis in travellers can be discontinued on the day of return from a malaria-endemic area instead of seven days after return as per currently recommended post-travel schedule. Methods: PubMed and Embase databases were searched to identify relevant studies. This PROSPERO-registered systematic review followed PRISMA guidelines. The search strategy included terms or synonyms relevant to AP combined with terms to identify articles relating to prophylactic use of AP and inhibitory and half-life properties of AP. Studies considered for inclusion were: randomized controlled trials, cohort studies, quasi-experimental studies, open-label trials, patient-control studies, cross-sectional studies; as well as case-series and non-clinical studies. Data on study design, characteristics of participants, interventions, and outcomes were extracted. Primary outcomes considered relevant were prophylactic efficacy and prolonged inhibitory activity and half-life properties of AP. Results: The initial search identified 1,482 publications, of which 40 were selected based on screening. Following full text review, 32 studies were included and categorized into two groups, namely studies in support of the current post-travel regimen (with a total of 2,866 subjects) and studies in support of an alternative regimen (with a total of 533 subjects). Conclusion: There is limited direct and indirect evidence to suggest that an abbreviated post-travel regimen for AP may be effective. Proguanil, however, has a short half-life and is essential for the synergistic effect of the combination. Stopping AP early may result in mono-prophylaxis with atovaquone and possibly select for atovaquone-resistant parasites. Furthermore, the quality of the studies in support of the current post-travel regimen outweighs the quality of the studies in support of an alternative short, post-travel regimen, and the total sample size of the studies to support stopping AP early comprises a small percentage of the total sample size of the studies performed to establish the efficacy of the current AP regimen. Additional research is required - especially from studies evaluating impact on malaria parasitaemia and clinical illness and conducted among travellers in high malaria risk settings - before an abbreviated regimen can be recommended in current practice. Prospero registration number: CRD42017055244.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationTravel Medicine and Infectious Disease 21 (2018) 3–20pt_PT
dc.identifier.doi10.1016/j.tmaid.2017.12.005pt_PT
dc.identifier.eissn1873-0442
dc.identifier.issn1477-8939
dc.identifier.urihttp://hdl.handle.net/10451/59480
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/journal/travel-medicine-and-infectious-diseasept_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectAtovaquone-proguanilpt_PT
dc.subjectAbbreviated regimept_PT
dc.subjectChemoprophylaxispt_PT
dc.subjectSystematic reviewpt_PT
dc.titleAbbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic reviewpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage20pt_PT
oaire.citation.startPage3pt_PT
oaire.citation.titleTravel Medicine and Infectious Diseasept_PT
oaire.citation.volume21pt_PT
person.familyNameHanscheid
person.givenNameThomas
person.identifier.orcid0000-0001-6353-9132
person.identifier.scopus-author-id7004266513
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication2fcee295-6474-439a-85af-fb3397f771df
relation.isAuthorOfPublication.latestForDiscovery2fcee295-6474-439a-85af-fb3397f771df

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
Abbreviated_atovaquone.pdf
Tamanho:
535.76 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição: